^
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
pemetrexed
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
carboplatin + pemetrexed
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
cisplatin + pemetrexed
Sensitive: A2 - Guideline
No biomarker
Mesothelioma
GC
Sensitive: A2 - Guideline
No biomarker
Mesothelioma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Mesothelioma
cisplatin + raltitrexed
Sensitive: A2 - Guideline
No biomarker
Mesothelioma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
carboplatin + raltitrexed
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
GC
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
ramucirumab
Sensitive: A2 - Guideline
High 4-gene inflammatory score
Mesothelioma
nivolumab + ipilimumab
Sensitive: B - Late Trials
PD-L1 expression
Malignant Pleural Mesothelioma
nivolumab
Sensitive: C1 - Off-label
BRCA1 mutation
Mesothelioma
rucaparib
Sensitive: C1 - Off-label
BAP1 mutation
Mesothelioma
tazemetostat
Sensitive: C2 – Inclusion Criteria
MSLN positive
Mesothelioma
TC-210
Sensitive: C2 – Inclusion Criteria
WT1 expression
Malignant Pleural Mesothelioma
nivolumab + galinpepimut-S
Sensitive: C3 – Early Trials
TMB-L
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant: C3 – Early Trials
TMB-L
Malignant Pleural Mesothelioma
PD-L1 inhibitor
Resistant: C3 – Early Trials
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant: C3 – Early Trials
BAP1 negative + BRCA1 mutation
Mesothelioma
rucaparib
Sensitive: C3 – Early Trials
BAP1 negative
Mesothelioma
rucaparib
Sensitive: C3 – Early Trials
MRE11A mutation
Mesothelioma
olaparib
Sensitive: C3 – Early Trials
BAP1 mutation
Mesothelioma
olaparib
Resistant: C3 – Early Trials
BRCA1 negative
Mesothelioma
rucaparib
Sensitive: C3 – Early Trials
BAP1 mutation
Mesothelioma
rucaparib
Sensitive: C3 – Early Trials
ERCC1 expression
Malignant Pleural Mesothelioma
GC
Sensitive: C3 – Early Trials
RRM1 expression
Malignant Pleural Mesothelioma
GC
Sensitive: C3 – Early Trials
MSLN overexpression
Malignant Pleural Mesothelioma
TC-210
Sensitive: C3 – Early Trials
ASS1 mutation
Malignant Pleural Mesothelioma
cisplatin + pemetrexed + pegargiminase
Sensitive: C3 – Early Trials
PD-L1 overexpression
Mesothelioma
pembrolizumab + nintedanib
Sensitive: C3 – Early Trials
CDKN2A negative
Mesothelioma
abemaciclib
Sensitive: C3 – Early Trials
PD-L1 overexpression
Malignant Pleural Mesothelioma
nivolumab
Sensitive: C4 – Case Studies
EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R
Mesothelioma
lorlatinib
Resistant: C4 – Case Studies
EML4-ALK I1171N + EML4-ALK L1196M
Malignant Pleural Mesothelioma
alectinib
Resistant: C4 – Case Studies
STRN-ALK rearrangement
Mesothelioma
crizotinib
Sensitive: C4 – Case Studies
STRN exon 2-ALK exon 20 fusion
Mesothelioma
cisplatin + pemetrexed
Resistant: C4 – Case Studies
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
Mesothelioma
pembrolizumab
Sensitive: C4 – Case Studies
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
Mesothelioma
cisplatin + carboplatin + pemetrexed + mitomycin
Resistant: C4 – Case Studies
STRN-ALK rearrangement
Mesothelioma
ABT 263
Sensitive: D – Preclinical
STRN-ALK rearrangement
Mesothelioma
cobimetinib
Sensitive: D – Preclinical
STRN-ALK rearrangement
Mesothelioma
ceritinib + PF-05212384
Sensitive: D – Preclinical
STRN-ALK rearrangement
Mesothelioma
ensartinib
Sensitive: D – Preclinical
STRN-ALK rearrangement
Mesothelioma
trametinib
Sensitive: D – Preclinical
STRN-ALK rearrangement
Mesothelioma
cobimetinib + ceritinib
Sensitive: D – Preclinical
STRN-ALK rearrangement
Mesothelioma
ceritinib
Sensitive: D – Preclinical
STRN-ALK rearrangement
Mesothelioma
brigatinib
Sensitive: D – Preclinical
STRN-ALK rearrangement
Mesothelioma
cisplatin + gemcitabine
Resistant: D – Preclinical
NF2 mutation
Mesothelioma
CBL0102
Sensitive: D – Preclinical
RB1 deletion
Mesothelioma
BI 6727
Sensitive: D – Preclinical
RB1 deletion
Mesothelioma
MLN8237
Sensitive: D – Preclinical
NF2 mutation
Mesothelioma
verteporfin
Sensitive: D – Preclinical
LATS1 mutation
Mesothelioma
verteporfin
Sensitive: D – Preclinical
LATS2 mutation
Mesothelioma
verteporfin
Sensitive: D – Preclinical
RASSF7 amplification
Mesothelioma
verteporfin
Sensitive: D – Preclinical
MSLN overexpression + PD-L1 overexpression
Mesothelioma
ATA3271
Sensitive: D – Preclinical
KRAS mutation
Mesothelioma
IK-930
Sensitive: D – Preclinical
EGFR mutation
Mesothelioma
IK-930
Sensitive: D – Preclinical